Mon, August 8, 2022
Fri, August 5, 2022
Thu, August 4, 2022

Liisa Bayko Downgraded (BCRX) to Hold and Held Target at $14 on, Aug 5th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -hold-and-held-target-at-14-on-aug-5th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Liisa Bayko of Evercore ISI Group, Downgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Hold and Held Target at $14 on, Aug 5th, 2022.

Liisa has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, all agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $14 on, Tuesday, April 12th, 2022
  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $14 on, Monday, April 11th, 2022

Publication Contributing Sources